InVivo Biosystems Blog

Revolutionizing Rare Disease Research: Unleashing the Power of RareResolve for Rapid Discovery in Rare Disease Medicine

As personalized medicine and the discovery of de novo variants that cause disease continue to grow, researchers are increasingly in need of alternative models

Whitepaper: What is IND?

As personalized medicine and the discovery of de novo variants that cause disease continue to grow, researchers are increasingly in need of alternative models

Fast, Cost Effective Compound Efficacy Testing using Zebrafish

As personalized medicine and the discovery of de novo variants that cause disease continue to grow, researchers are increasingly in need of alternative models
Leaky gut assays feature image

Leaky Gut Assays in Animal Models

Inflammation in your intestine is detrimental to overall health, and can create many complications. So how is this phenomenon researched?
No animals, new drugs, no problem

New drugs, No Animals, No Problem. The FDA announced legislative changes – drugs are no longer required to be tested in animals before moving to human trials. What does that mean?

The FDA announced animal testing no longer necessary for drug discovery. In this article we discuss the implications for USA’s drug pipeline.
WHAM with CRISPR - re-imaging how rare disease therapeutics are developed

Whole-gene Humanized Animal Models (WHAM) with CRISPR – Re-imagining how Rare Disease therapeutics are developed

Traditional modeling of patient variants in vivo has two limitations which can be overcome utilizing InVivo Biosystems’ patented WHAM-method.
customer story: zebrafish CRO feature image

Using Zebrafish CRO to Accelerate Grant Application Process

Dr Quintana chose to leverage InVivo Biosystems’ fully validated custom injection mixes to create point mutations that target the protein HFC1 in zebrafish
WHAM - humanized animal models for drug discovery

WHAMyness – How Gene-Humanized Animals Can Dramatically Improve Drug Discovery

Current in vivo platforms are limited in their ability to identify drug candidates – Whole-gene Humanized Animal Models can help.

America is finally investing in Biotechnology & Biomanufacturing in a Big Way

In this article we discuss what President Biden’s New Executive Order means for America’s place in the biotech and biomanufacturing fields.

The Path to Affordable Therapeutics in Rare Disease – Tackling Congenital Disorder of Glycosylation in the PMM2 gene [Customer Story].

[Patent Announcement] InVivo Biosystems has officially been issued a patent on WHAM-humanization in the nematode, C. elegans

We are excited to announce that the USPTO has issued a patent titled, ‘Transgenic animal phenotyping platform and uses thereof’ to InVivo Biosystems.

Looking at Gene Paralogs across both zebrafish and C. elegans Model Organisms [Customer Story]

Drs Pruyne & Amack leveraged InVivo Biosystems’ Custom Injection Mix to design and create a novel zebrafish line.

Part Two: Is Drug Repurposing the New Model for Drug Discovery?

Part One: An Overview of Drug Repurposing

Chemicals Models of Parkinson’s Disease in Larval Zebrafish

Poking its way into Western Medicine: How Acupuncture Could Help Ease Chronic Pain

A Natural Fit – Using Zebrafish to Evaluate Natural Compounds for Anti-Inflammatory Properties

Quick Guide to Natural Products: What They are and How They Impact You

Summary: This Earth Month we at InVivo Biosystems are thinking about how we utilize Earth’s resources in biomedicine – from animal systems that enable us
microbiome models feature image

Models to Research Microbiome

In this article, we will discuss the commonly used model organisms for microbiome research, and what insights they can provide.
zfish as drug discovery tool feature image

Lost and Found: Zebrafish as a Drug Discovery Tool

Summary Zebrafish models largely began as a way to research developmental biology, however, their potential to be a preclinical model of human disease quickly became

Neuroscience Models: Transgenic Mice, Zebrafish, C. Elegans – And Jellyfish?

From ED to AD: a drug repurposing success? How a performance-enhancing drug is giving insight into dementia

Recently, researchers at Cleveland Clinic’s Genomic Medicine Institute published an article in Nature Aging which has caused quite a stir in the medical community and

The In (vitro, vivo, silico)s and Outs of Research

Experiments fall into three categories – in vivo, in vitro, and in silico studies, and all of them have a different, but important role in

The Discrepancy Between Sexes: Clinical Models & Clinical Trials

Pharmaceutical drugs go through a rigorous process that tests their safety and efficacy before gaining FDA approval and being put on the commercial market. Traditionally,

A Closer Look at Nutraceutical Regulations: How Does the USA Compare?

In this article we will explore how the nutraceutical regulations compare in the USA and abroad, asking how they are defined in each country, what

Recent Nutraceutical Research

We’ve rounded up some of the recent publications that we’ve been enjoying – click their links below to see what’s new in this space!

Testing the Neuroprotective Effect of a Lead Compound Using C. elegans for Fast and Cost-Effective Answers [Customer Story]

FDA versus FTC Approval – What is the Difference?

In this article we aim to clarify the intent behind these therapies and what their labelling means by asking: Why aren’t nutraceutical products FDA approved?

HIV, COVID-19, Alzheimer’s: The Impact of The FDA’s Expedited Programs and What’s Next

The FDA’s emergency use authorization (EUA) of the COVID-19 vaccines has brought the approval process of vaccines and drugs into public consciousness, however, the FDA’s

How Can a Drug Get to Market Faster? Explaining the FDA’s Expedited Drug Tracks

Getting a drug to market is notoriously difficult, taking 7-10 years and costing hundreds of millions of dollars. This, coupled with the Covid-19 pandemic’s impact

New Alzheimer’s Drug: Helpful or Just Expedient?

Aducanumab has been plagued with controversy since it was announced. We take a look to see if it is helpful, or just expedient.

Rising Healthcare Costs? Non-Mammalian Models To The Rescue

The Application of Hypersensitivity Assays to the Discovery of Therapeutics

Using Humanization we can take advantage of the ancient biology between humans and other organisms to create stand-ins – patient avatars – for drug screening

Let’s Fail Faster: Why Scientific Failures Should be Accepted as Progress

In the scientific community there is an emphasis on positive results: getting published, having a drug be approved, etc. However, crucial learning happens when experiments

The DrugAge Database: Showcasing C. Elegans In Longevity Research

Drug Repurposing for Neurological Disorders

Neurological disorders are extremely widespread, affecting over 1 billion people worldwide, and have debilitating effects, impacting the brain, spinal cord, cranial nerves, and peripheral nerves.

Whole Gene Humanization for Personalized Medicine Applications

We have found whole gene humanization can create a platform for highly translatable results in a model organism. Currently there is a big need for

How to Design a Good Phenotype Based Drug Discovery Program, and Why It Matters.

With the advent of the molecular biology revolution and the human genome project in the 1990s there was a historic shift toward target-based drug

Understanding GPCRs Using Humanized C. elegans

Our CSO, Dr. Chris Hopkins presented at DR. GPCR SUMMIT 2020 on why C. elegans is an ideal model to study the underlying principles of GPCRs.

Longevity Studies Using C. elegans to Identify Potential Anti-Aging Compounds [Customer Story]

Dr. Vollmer shares his experience working with us and how the Longevity Platform delivers the results he needs within his timeline and budget.

Seventeen Minutes of Science: Viral Gene Therapies and Their Potential Use Against COVID-19

Tune in weekly to our virtual series “Seventeen Minutes of Science” every Tuesday at 11am PST / 2pm ET where we go live on Facebook

Bacteria, Protozoa And Nematodes, Oh My!: Seeking New Drugs Against COVID-19

Seventeen Minutes of Science: Spreading out from Kendall (Episode 6)

[New Webinar] A Shortcut to Understanding Longevity

Zebrafish and C. elegans in ALS: tightening the bench-to-clinic gap

While advances in molecular imaging, high-throughput screening, genomics and techniques like CRISPR-Cas9 gene editing have dramatically enhanced our understanding of the human body and disease,

wMicroTracker Applications: Drug Screening

The wMicroTracker is a great product to add to your drug screening toolkit. Check out the application sheet below to see how easy it is

Worms, Flies or Fish? A Comparison of Common Model Organisms — Part 2: Models for human diseases

Non-mammalian model organisms are typically used in early research to deliver fast answers to a discovery problem. The most popular model organisms in biological and

Worms, Flies or Fish? A Comparison of Common Model Organisms – Part 1: Models for Biomedical Research

Non-mammalian model organisms are typically used in early research to deliver fast answers to a discovery problem. The most popular model organisms in biological and
Enlarge C. elegans Models | InVivo Biosystems

Are worms the future of drug development?

NemaMetrix’s ScreenChip collects live-animal, high-throughput C. elegans electropharyngeograms (EPGs), which are an indication of overall organism health for drug development. Read the blog post on BioCoder
Load More

Connect with us